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In addition to HPV, high parity and hormonal contraceptives have been associated with cer-
vical cancer (CC). However, most of the evidence comes from retrospective case-control
studies. The aim of this study is to prospectively evaluate associations between hormonal
factors and risk of developing cervical intraepithelial neoplasia grade 3 (CIN3)/carcinoma in
situ (CIS) and invasive cervical cancer (ICC).
Methods and Findings
We followed a cohort of 308,036 women recruited in the European Prospective Investiga-
tion into Cancer and Nutrition (EPIC) Study. At enrollment, participants completed a ques-
tionnaire and provided serum. After a 9-year median follow-up, 261 ICC and 804 CIN3/CIS
cases were reported. In a nested case-control study, the sera from 609 cases and 1,218
matched controls were tested for L1 antibodies against HPV types 11,16,18,31,33,35,45,
52,58, and antibodies against Chlamydia trachomatis and Human herpesvirus 2. Multivari-
ate analyses were performed to estimate hazard ratios (HR), odds ratios (OR) and corre-
sponding 95% confidence intervals (CI). The cohort analysis showed that number of full-
term pregnancies was positively associated with CIN3/CIS risk (p-trend = 0.03). Duration of
oral contraceptives use was associated with a significantly increased risk of both CIN3/CIS
and ICC (HR = 1.6 and HR = 1.8 respectively for15 years versus never use). Ever use of
menopausal hormone therapy was associated with a reduced risk of ICC (HR = 0.5, 95%
CI: 0.4–0.8). A non-significant reduced risk of ICC with ever use of intrauterine devices
(IUD) was found in the nested case-control analysis (OR = 0.6). Analyses restricted to all
cases and HPV seropositive controls yielded similar results, revealing a significant inverse
association with IUD for combined CIN3/CIS and ICC (OR = 0.7).
Conclusions
Even though HPV is the necessary cause of CC, our results suggest that several hormonal
factors are risk factors for cervical carcinogenesis. Adherence to current cervical cancer
screening guidelines should minimize the increased risk of CC associated with these hor-
monal risk factors.
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Introduction
Cervical cancer (CC) is the fourth most common cancer among women worldwide with an esti-
mated 528,000 new cases and the fourth most common cause of female death from cancer with
an estimated 266,000 deaths in 2012 [1]. Human papillomavirus (HPV) is one of the most com-
mon sexually transmitted infections worldwide. In fact, most sexually active women will be
infected with HPV during their lifetime, although the majority of HPV infections are cleared
within 2 years [2,3]. HPV genotypes are classified as low-risk or high-risk based on their associa-
tion with cervical cancer (CC) [4]. It is well established that persistent infection with high-risk
HPV genotypes is the necessary although not sufficient cause of CC [5]. Thus, the involvement
of other factors, in addition to HPV, is needed to induce cervical carcinogenesis. High parity and
hormonal contraceptives have long been recognized as potential cofactors of CC [5]. A compre-
hensive review conducted by the International Agency for Research on Cancer (IARC) classified
the use of combined oral contraceptives (OC) as carcinogenic to humans, and this was partly
based on the reported associations with CC [6]. A collaborative pooled reanalysis evaluating CC,
hormonal contraceptives and parity found an increased risk of CC in current and long-term OC
users, a reduced risk after stopping these hormones [7], and positive associations with both num-
ber of full-term pregnancies (FTP) and an early age at first FTP [8]. In addition, results from the
European Prospective Investigation into Cancer and Nutrition (EPIC) showed that circulating
levels of sex steroid hormones testosterone and possibly estradiol were also positively involved in
the etiology of CC [9]. However, even though these associations are generally consistent across
studies, it must be noted that the evidence for a role of hormones in cervical carcinogenesis is
mostly derived from retrospective case-control studies that did not always take into account
HPV. Thus the aim of this study is to prospectively examine potential associations between hor-
monal factors and risk of developing cervical cancer and pre-cancer using data from a large pro-
spective study that additionally uses serological markers of HPV exposure.
Materials and Methods
The EPIC cohort study
The EPIC study is a large prospective cohort study including 521,448 participants (367,993
women and 153,455 men) recruited between 1992 and 2000 through 23 centres in 10 European
countries: Denmark, France, Germany, Greece, Italy, the Netherlands, Norway, Spain, Sweden,
and the United Kingdom. Most of the EPIC participants were between the ages of 35 and 70
years. The study procedures have been described in detail elsewhere [9,10]. At recruitment, partic-
ipants gave their written informed consent and completed questionnaires on their diet, medical
and lifestyle history. They were also invited to provide blood samples for future testing of markers
of interest. The EPIC study was approved by the ethical review committees from each center.
Study population
Of the approximately 370,000 women enrolled in the study, women were not eligible for this
analysis if they had prevalent cancer or pre-cancer (n = 22,180), incomplete follow-up
(n = 2,295), hysterectomy (n = 34,973) or incomplete lifestyle questionnaire (n = 509) at base-
line. This left a total of 308,036 women in these analyses.
Identification of cases and follow-up
Cases of cervical intraepithelial neoplasia grade 3 (CIN3)/carcinoma in situ (CIS) and invasive
cervical cancer (ICC) were identified through several methods, including a record linkage with
population-based cancer registries (Denmark, Italy, the Netherlands, Norway, Spain, Sweden
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and the United Kingdom), health insurance records, hospital-based cancer and pathology regis-
tries and active follow-up of subjects (France, Germany and Greece). Data on vital status were
obtained frommortality registries at regional and national level. Cervical cancer cases included
only those women with first primary incident cancer according to the International Classification
of Diseases, 10th revision (code C53: cervix uteri). Contrary to ICC, ascertainment of CIN3/CIS
cases was not systematically done in all cancer registries and EPIC centers. Follow-up time was
calculated between the date at recruitment and the date at diagnosis for cases or the date at cen-
soring (death, loss of follow-up or end of follow-up) for non-cases. The end of follow-up ranged
fromDecember 2003 to December 2006, depending on the center. The median follow-up time in
this cohort was around 9 years (25th-75th percentile: 7.5–10.8 years) contributing a total of
2,775,235 person-year. Among the 308,036 women included in the final analysis 1,065 cases were
identified: 261 ICC cases and 804 CIN3/CIS cases. Detailed tumor histology was specified for 953
cases (89%), of which 901 (95%) were classified as squamous cell carcinoma (SCC, 712 in situ
and 189 invasive) and 52 (5%) as adenocarcinoma (9 in situ and 43 invasive).
Nested case-control study
A nested case-control study within the EPIC cohort was conducted to allow for the adjustment
by serological markers of HPV and other sexually transmitted infections (STIs), even though
this strategy involves a lower number of subjects. For each case with available blood sample,
two matched control subjects were randomly selected from the cancer-free cohort of women
that were at risk at the time of diagnosis of the corresponding case. Matching criteria included:
study center, age at recruitment (5 year intervals), menopausal status (pre-, peri- and postmen-
opausal), follow-up time, date, time and fasting status at blood collection, and, among premen-
opausal women, phase of the menstrual cycle [9]. Approximately 70% of ICC cases and 53% of
CIN3/CIS cases identified in the cohort provided serum samples, yielding a total of 609 cases
(184 ICC and 425 CIN3/CIS) and 1,218 controls for the analyses.
Serological testing
HPV serology was performed at the German Cancer Research Centre in Heidelberg, Germany.
Assay procedures have been explained in detail previously [11,12]. Briefly, antibodies to the
capsid protein L1 of high-risk mucosal HPV types 16, 18, 31, 33, 35, 45, 52, and 58, and of low-
risk mucosal HPV type 11 were tested by Glutathione S-transferase capture and fluorescent
bead-based multiplex serology [13–15]. For the nested case-control analyses, HPV L1 seroposi-
tivity refers to that for at least one of the nine HPV types analyzed, and high-risk HPV L1 sero-
positivity refers to positivity for at least one of the eight high-risk HPV types analyzed.
Serum antibodies against Chlamydia trachomatis (CT) and Human herpesvirus 2 (HHV-2)
were tested at the Hospital of Santa Creu i Sant Pau in Barcelona, Spain. We used the commer-
cial assay Chlamydia MIF IgG (Focus Diagnostics, Cypress, CA, USA) for the detection of CT
IgG serum antibodies performed by microimmunofluorescence, and the commercial kit Her-
peSelect1 2 ELISA IgG (Focus Diagnostics, Cypress, CA, USA) for the detection of antibodies
against HHV-2 evaluated by an enzyme immunoassay. The positive results of HHV-2 antibod-
ies were confirmed by a membrane-based immunoassay with the biokitHSV-2 Rapid Test
(Biokit USA, Lexington, MA, USA).
All serological assays were performed blinded to the subject’s characteristics.
Statistical analyses
Multivariate hazard ratios (HR) and 95% confidence intervals (CI) were estimated to evaluate
the risk of CIN3/CIS and ICC in relation to several hormonal risk factors using Cox
Hormonal Factors and Cervical Cancer in EPIC
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proportional hazard regression models. In all analyses, age was used as the underlying time var-
iable, and the models were stratified by age at recruitment (in one-year categories) and study
center. The proportional hazards assumption was evaluated for all models fitted using tests
based on weighted residuals. Tests for linear trend were performed using continuous variables.
We estimated HR for variables related with hormonal factors collected at recruitment. The
parity-related variables evaluated in these analyses were the following: ever FTP (never, ever),
number of FTP (1, 2, 3,4), age at first FTP (30, 25–29, 21–24,20 years old), and number
of induced abortions (1,2) if any (never, ever). Self-reported baseline menopausal status was
defined as postmenopausal (no menses in the last 12 months or bilateral ovariectomy), peri-
menopausal (<9 menses in the past 12 months), and premenopausal (regular menses in the
past 12 months). Women with unknown menopausal status were classified as postmenopausal
if they were 55 years old or more, perimenopausal if they were between 46 and 55 years of age
and premenopausal when they were less than 46 years of age at recruitment. We estimated the
cumulative years of menstrual cycling as the difference between the age at menopause (for
postmenopausal women) or of the age at recruitment (for pre- and perimenopausal women)
and the age at menarche minus the total time being pregnant (number of FTP x 9 months) and
the total time using OCs; this variable was categorized in quintiles:19.50, 19.51–26.76,
26.77–31.50, 31.51–35.50,35.51 years. The exogenous hormone-related factors evaluated
included: OC use (never, ever, past, current), duration of OC use (1, 2–4, 5–9, 10–14,15
years), latency of OC use or time since first use (10, 11–20,21 years), and recency of OC
use or time since last use (5, 6–14,15 years) among past OC users. Use of intrauterine
device (IUD) was also analyzed and dichotomized as never and ever IUD use. Among post-
and perimenopausal women, use of menopausal hormone therapy (HT) was evaluated as: HT
use (never, ever, past, current), duration of HT use (1, 2–4,5 years) and HT formulation
(estrogen alone, progesterone alone, combination of estrogen/progesterone). Ovariectomy was
also assessed (no, unilateral, bilateral). Combined variables using number of FTP and age at
first FTP, duration and recency of OC use, and number of FTP and duration of OC use were
also created and evaluated. The following variables were also analyzed but not included in the
tables presented because they were either collinear with the final selected variables or not asso-
ciated with risk in any of the analyses: time since first FTP, pregnancies, live births, stillbirths,
miscarriages, breastfeeding, age started and stopped OC use, use of different contraceptives
(condoms, spermicidal creams, tubal ligation, rhythm methods, diaphragm, vasectomy), age
started HT use, type of HT (oral, injectable, topical), menopausal status, age at menarche, and
age at menopause.
We used stepwise regression modeling to assess potential confounding by other variables
such as: body mass index (BMI, underweight (<18.5), normal (18.5–25), overweight (25–30),
obese (30)), marital status (single, married/cohabiting, divorced/separated, widowed),educa-
tion level (none, primary school, technical/professional school, secondary school, university
degree), physical activity (inactive, moderately inactive, moderately active, and active, using a
validated Cambridge Physical Activity Index [16]), and smoking habits (never, former and
duration<15 years, former and duration15 years, current and intensity<10 cig/day, current
and intensity10 cig/day). Number of FTP (0, 1, 2, 3,4), OC use and duration (never, past
for<10 years, past for10 years, current for<10 years, current for10 years), and meno-
pausal status with HT use (premenopausal, peri- and postmenopausal and non HT users, peri-
and postmenopausal and HT users) were used as adjusting variables when appropriate.
In the nested case-control analysis, multivariate odds ratios (OR) and 95% CI were esti-
mated to evaluate the risk of CIN3/CIS and ICC in relation to hormonal factors using condi-
tional logistic regression models. Models were adjusted for HPV L1 serology, CT serology,
HHV-2 serology, and other potential confounding factors (BMI, marital status, education
Hormonal Factors and Cervical Cancer in EPIC
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level, physical activity, smoking habits, OC use and duration, number of FTP and menopausal
status with HT use (when appropriate)). Unconditional logistic regression analyses among all
cases and HPV L1 seropositive controls were also performed, including the matching variables
in the models as adjusting covariates. Tests for interaction among hormonal variables and
other risk factors were based on the likelihood ratio test comparing the models with and with-
out the interaction terms.
When applicable, variables included a missing or unknown category in order to avoid the
exclusion of participants in the regression models. All statistical tests were 2-tailed, and p-values
below 0.05 were considered statistically significant. Statistical analyses were performed using the
R programing language (R Development Core Team, 2005, http://www.R-project.org).
Ethics statement
All participants gave written informed consent, and the study was approved by the local ethics
committees in the participating countries (Athens: University of Athens Medical School; Cam-
bridge: Norwich District Ethics Committee; Denmark (Aarhus, Copenhagen): The National
Committee on Health Research Ethics; France (Paris): Comité de Protection des Personnes;
Heidelberg: Ethics Committee of the Heidelberg University Medical School; International
Agency for Research on Cancer: IARC Ethics Committee; Imperial College: Imperial College
Research Ethics Committee [ICREC]; Italy (Florence, Milan, Naples, Ragusa, Turin): Comitato
Etico Indipendente, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; Florence:
Comitato Etico Locale Azienda Sanitaria di Firenze; Malmo: Ethics Committee of Lundst
University; Netherlands (Bilthoven and Utrecht): The Medical Ethical Committee (METC =
Medisch Ethische Toetsingscommissie) of the University Medical Center Utrecht (UMCU),
Utrecht, the Netherlands; Norway: Regional ethical committee for Northern Norway and the
Norwegian Data Inspectorate; Oxford: Scotland A Research Ethics Committee; Potsdam:
Ethikkommission der Landesärztekammer Brandenburg Cottbus, Deutschland; Spain (Astu-
rias, Barcelona, Granada, Murcia, Navarre, San Sebastian): CEIC Comité de Ética de Investiga-
ción Clínica; Turin: Human Genetics Foundation Torino: Ethics Committee; Umea: Umea
Regional Ethical Review Board) and the Internal Review Board of the International Agency for
Research on Cancer.
Results
Baseline characteristics for cases and non-cases included in the cohort analysis have been
reported previously (S1 Table) [11]. In brief, most CIN3/CIS cases were recruited from the
United Kingdom (37.1%), Sweden (20.8%) and Norway (15.0%), and most of the ICC cases
were from Sweden (16.9%), the United Kingdom (13.4%), Denmark (12.6%) and France
(11.5%). CIN3/CIS cases were younger than ICC cases. As compared to non-cases, women
with CIN3/CIS or ICC were more likely to be single or separated, to smoke, to have ever used
OCs, and to be premenopausal. The characteristics of the women included in the nested case-
control analysis have already been described in two previous articles [11,12].
Table 1 shows associations between factors related to endogenous hormones and risk of
developing CIN3/CIS and ICC by study design (full cohort study and nested case-control
study). In both analyses the risk of CIN3/CIS increased significantly with increasing number of
FTP. In contrast, for ICC, a non significant decreased risk was observed among women who
ever had a FTP. A decreased risk of CIN3/CIS and ICC was observed with decreasing age at
first FTP, but only in the case-control study and this was only statistically significant for CIN3/
CIS. In both study designs, a non significant decreased risk of CIN3/CIS was observed among
women who had more than one induced abortion. However, for ICC an increased risk was
Hormonal Factors and Cervical Cancer in EPIC
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Table 1. Risk of CIN3/CIS and ICC of the cervix according to factors related with endogenous hormones.
Risk factor Cohort study Nested case-control study
CIN3/CIS ICC CIN3/CIS ICC
Non-cases / Cases HR
(95% CI) 1
Non-cases / Cases HR
(95% CI) 1
Controls / Cases OR
(95% CI) 2
Controls / Cases OR
(95% CI) 2
Number of FTP
Never 45,228 / 191 1.0 (ref) 45,419 / 45 1.0 (ref) 139 / 51 1.0 (ref) 43 / 30 1.0 (ref)
Ever 246,823 / 516 1.5 (1.2–1.9) 247,339 / 191 0.7 (0.5–1.0) 543 / 288 2.0 (1.2–3.2) 281 / 131 0.8 (0.4–1.5)
1 44,007 / 116 1.4 (1.0–1.8) 44,123 / 36 0.7 (0.5–1.2) 132 / 71 1.7 (1.0–2.9) 42 / 26 0.8 (0.3–2.0)
2 114,956 / 237 1.4 (1.1–1.9) 115,193 / 82 0.7 (0.4–1.0) 247 / 132 2.1 (1.2–3.4) 153 / 53 0.5 (0.2–1.1)
3 54,107 / 94 1.4 (1.0–1.9) 54,201 / 40 0.7 (0.4–1.2) 97 / 46 2.1 (1.2–3.8) 55 / 28 1.0 (0.4–2.3)
4 23,545 / 51 2.3 (1.6–3.3) 23,596 / 23 0.9 (0.5–1.6) 42 / 28 2.6 (1.3–5.3) 18 / 16 1.5 (0.5–4.4)
p for trend among ever
ftp
0.03 0.4 0.2 0.02
Age at ﬁrst FTP
(years) 3
30 35,122 / 71 1.0 (ref) 35,193 / 22 1.0 (ref) 69 / 39 1.0 (ref) 22 / 13 1.0 (ref)
25–29 85,567 / 161 1.1 (0.8–1.4) 85,728 / 66 1.2 (0.7–2.0) 164 / 90 1.0 (0.6–1.8) 104 / 48 0.8 (0.2–2.9)
21–24 89,750 / 181 1.1 (0.8–1.5) 89,931 / 65 1.0 (0.6–1.6) 192 / 106 0.7 (0.4–1.3) 107 / 41 0.6 (0.2–1.9)
20 35,372 / 101 1.2 (0.9–1.7) 35,473 / 36 1.1 (0.6–2.0) 113 / 52 0.5 (0.3–1.1) 47 / 27 1.0 (0.2–4.3)
p for trend among ever
ftp
0.2 0.8 0.03 0.9
Number of induced
abortions 4
Never 157,566 / 278 1.0 (ref) 157,844 / 99 1.0 (ref) 295 / 166 1.0 (ref) 180 / 70 1.0 (ref)
Ever 41,079 / 77 0.9 (0.7–1.1) 41,156 / 53 1.9 (1.3–2.7) 84 / 45 0.6 (0.4–1.0) 57 / 41 1.7 (0.8–3.4)
1 28,058 / 63 1.0 (0.7–1.3) 28,121 / 36 1.9 (1.3–2.8) 63 / 36 0.6 (0.4–1.2) 38 / 26 1.4 (0.6–3.4)





Quintile 1 47,020 / 270 1.0 (ref) 47,290 / 57 1.0(ref) 126 / 78 1.0 (ref) 43 / 26 1.0 (ref)
Quintile 2 46,953 / 118 0.9 (0.7–1.1) 47,071 / 29 0.5 (0.3–0.8) 124 / 64 1.0 (0.6–1.7) 39 / 28 1.6 (0.6–3.8)
Quintile 3 48,557 / 91 0.8 (0.6–1.1) 48,648 / 49 0.8 (0.5–1.3) 106 / 57 0.8 (0.5–1.4) 66 / 22 0.5 (0.2–1.2)
Quintile 4 47,855 / 63 0.7 (0.5–1.0) 47,918 / 36 0.6 (0.4–1.1) 111 / 43 0.5 (0.3–0.9) 60 / 39 1.0 (0.4–2.3)
Quintile 5 44,733 / 47 0.7 (0.5–1.1) 44,780 / 24 0.4 (0.2–0.8) 114 / 49 0.5 (0.3–0.9) 74 / 23 0.7 (0.3–1.7)
p for trend 0.009 0.005 0.01 0.6
CIN3: cervical intraepithelial neoplasia grade 3; CIS: carcinoma in situ; ICC: invasive cervical cancer; HR: hazard ratio; OR: odds ratio; CI: conﬁdence
interval; FTP: full-term pregnancy; OC: oral contraceptives; HT: hormone therapy. The number of cases does not add up the total number of cases
because of missing values. Bold font indicates a statistically signiﬁcant effect (p<0.05).
1 Models were adjusted by body mass index, marital status, level education, physical activity, smoking habits, OC use and duration and menopausal
status with HT use.
2 Conditional regression models were adjusted by HPV L1 serology, Chlamydia trachomatis serology, Human herpesvirus 2 serology, body mass index,
marital status, level education, physical activity, smoking habits, OC use and duration and menopausal status with HT use. See methods for list matching
variables.
3 Among parous women.
4 Excludes Bilthoven, Sweden and Norway because information was not collected for this variable.
5 Model not adjusted by OC use and duration because of co-linearity with cumulative duration of menstrual cycles. For cohort study, quintiles correspond
to: q1: 19.50; q2: 19.51–26.76; q3: 26.77–31.50; q4: 31.51–35.50; q5: 35.51. For nested case-control study, quintiles correspond to: q1: 14.66; q2:
14.67–24.23; q3: 24.24–29.17; q4: 29.18–33.75; q5: 33.76.
doi:10.1371/journal.pone.0147029.t001
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found among women who had at least one induced abortion but the association was statisti-
cally significant only in the cohort study. When analyses were adjusted or stratified by number
of FTP, the magnitude of the point estimates of the associations with both outcomes remained
mostly unchanged (data not shown). Women with higher lifetime years of menstrual cycles
had a lower risk of CIN3/CIS in both studies and of ICC in the cohort study.
When analyses were restricted to parous women and mutually adjusted for number of FTP
and age at first FTP, the effect of number of FTP for CIN3/CIS risk was maintained in the full
cohort analysis (HR = 1.6, 95% CI: 1.1–2.3), and was of borderline statistical significance in the
nested case-control study (OR = 2.1, 95% CI: 1.0–4.6; data not shown). No associations were
found for ICC risk.
Table 2 summarizes associations with factors related to exogenous hormones. Current use
of OCs and increasing years of use were both associated with CIN3/CIS and ICC in the cohort
study, even though the trend was only statistically significant for CIN3/CIS. As compared to
current users, increasing years since last OC use was associated with a reduction in the risk of
developing CIN3/CIS in the cohort study. In the case-control study associations were found in
the same direction but did not reach statistical significance. Ever use of HT among peri- and
postmenopausal women significantly decreased the risk of ICC in both studies. We found a
decreased risk of ICC with duration of HT use but the trend did not reach statistical signifi-
cance. In contrast, for CIN3/CIS we found a statistically significant reduced risk with years of
HT in the case-control study. Similar results were obtained when analyses where restricted to
postmenopausal women only (data not shown). We also assessed the effect of HT formulation
finding a non significant increased risk of CIN3/CIS for users of menopausal estrogens alone
(HR = 1.7, 95% CI: 0.9–3.1, for ever versus never users) and a lack of association for combined
formulations (data not shown). The effect of progestin alone could not be assessed due to the
low number of exposed subjects. For ICC, most exposed cases used some kind of combination
of hormones showing a borderline inverse association (HR = 0.6, 95% CI: 0.3–1.0, for ever ver-
sus never users). There were not enough cases to assess the effect of estrogen or progestin alone
(data not shown). Concerning IUD use, a non significant inverse association with both CIN3/
CIS and ICC risk was observed in the nested case-control study.
When the combined effect of duration and recency of OC use was evaluated, the risk of
CIN3/CIS declined progressively with increasing years since last use (data not shown). This
pattern was not observed for ICC risk.
In both study designs, the combined effect of number of FTP and duration of OC use was
analyzed, and showed a significant increased risk of CIN3/CIS with increasing number of FTP
within each category of OC use (S2 Table). Women with 4 or more FTP had a four-fold risk
within each category of OC use as compared to women who were nulliparous and never used
OCs. The test of interaction between OC use and FTP reached statistical significance in the
cohort study (p = 0.004). In contrast, for ICC we only found a marginal increased risk among
multiparous women who used OCs for more than 5 years in the cohort study.
Concerning associations by histological type, the risk of SCC showed the same overall pat-
tern: increased risk of CIS with number of FTP and years of OC use and decreased risk with
years of HT use, and increased risk of invasive SCC with years of OC use and decreased risk
with years of HT use (data not shown). Regarding adenocarcinomas, associations could not be
evaluated accurately because of the small number of cases (52 cases in the cohort study and 33
cases in the nested case-control study for both in situ and invasive adenocarcinomas). Never-
theless, these analyses showed non significant and weak positive associations with number of
FTP and OC use for invasive adenocarcinoma, and a non significant inverse association with
HT use (data not shown).
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Table 2. Risk of CIN3/CIS and ICC of the cervix according to factors related with exogenous hormones.
Risk factor Cohort study Nested case-control study
CIN3/CIS ICC CIN3/CIS ICC
Non-cases / Cases HR (95% CI) 1 Non-cases / Cases HR (95% CI) 1 Controls / Cases OR (95% CI) 2 Controls / Cases OR (95% CI) 2
IUD use 3
Never 170,843 / 371 1.0 (ref) 171,214 / 144 1.0 (ref) 325 / 160 1.0 (ref) 194 / 106 1.0 (ref)
Ever 63,677 / 136 1.1 (0.9–1.4) 63,813 / 43 0.9 (0.6–1.3) 160 / 82 0.8 (0.5–1.3) 70 / 28 0.6 (0.3–1.2)
OC use
Never 121,117 / 169 1.0 (ref) 121,286 / 76 1.0 (ref) 225 / 99 1.0 (ref) 139 / 56 1.0 (ref)
Ever 176,993 / 548 1.1 (0.9–1.3) 177,541 / 165 1.6 (1.1–2.3) 466 / 244 1.1 (0.8–1.5) 186 / 109 1.5 (0.8–2.6)
Past 152,658 / 411 1.0 (0.9–1.3) 153,069 / 134 1.6 (1.1–2.2) 392 / 197 1.0 (0.7–1.5) 158 / 86 1.3 (0.7–2.4)
Current 17,384 / 127 1.8 (1.4–2.4) 17,511 / 22 2.2 (1.3–4.0) 57 / 41 1.7 (0.9–3.1) 24 / 17 2.2 (0.7–6.7)
Duration of OC use
(years)
Never 121,117 / 169 1.0 (ref) 121,286 / 76 1.0 (ref) 225 / 99 1.0 (ref) 139 / 56 1.0 (ref)
1 31,867 / 78 1.0 (0.8–1.3) 31,945 / 27 1.5 (0.9–2.4) 180 / 82 1.0 (0.6–1.5) 76 / 36 1.1 (0.6–2.2)
2–4 40,168 / 127 1.1 (0.8–1.4) 40,295 / 27 1.3 (0.8–2.0)
5–9 38,816 / 136 1.1 (0.9–1.4) 38,952 / 41 2.0 (1.3–3.0) 108 / 54 1.1 (0.7–1.7) 38 / 22 1.6 (0.7–3.7)
10–14 26,969 / 90 1.2 (0.9–1.6) 27,059 / 26 1.6 (1.0–2.6) 138 / 94 1.6 (1.0–2.5) 63 / 42 1.5 (0.7–3.1)
15 23,395 / 82 1.6 (1.2–2.2) 23,477 / 28 1.8 (1.1–2.9)
p for trend among OC
users
0.01 0.2 0.2 0.9
Recency of OC use
(years) 4,5
Current 7,678 / 95 1.0 (ref) 7,773 / 8 1.0 (ref) 32 / 20 1.0 (ref) 10 / 12 1.0 (ref) 7
5 9,662 / 79 0.7 (0.5–1.0) 9,741 / 11 1.1 (0.4–2.8) 30 / 21 1.0 (0.2–4.2)
6–14 17,368 / 60 0.6 (0.4–0.8) 17,428 / 14 0.8 (0.3–2.0) 44 / 21 0.4 (0.1–1.9) 27 / 11 -
15 25,681 / 45 0.6 (0.4–0.9) 25,726 / 25 1.0 (0.4–2.5) 48 / 22 0.6 (0.1–5.0) 32 / 20 -
p for trend among past OC
users
0.2 0.7 - -
HT use 6
Never 114,271 / 149 1.0 (ref) 114,420 / 94 1.0 (ref) 170 / 83 1.0 (ref) 107 / 67 1.0 (ref)
Ever 63,839 / 131 1.2 (0.9–1.5) 63,970 / 31 0.5 (0.4–0.8) 149 / 84 0.9 (0.6–1.5) 72 / 18 0.3 (0.1–0.7)
Past 18,508 / 22 1.0 (0.6–1.5) 18,530 / 11 0.6 (0.3–1.2) 42 / 17 0.7 (0.3–1.4) 19 / 8 0.6 (0.2–2.0)
Current 43,110 / 102 1.3 (1.0–1.7) 43,212 / 19 0.5 (0.3–0.8) 102 / 61 1.1 (0.7–1.9) 51 / 10 0.2 (0.1–0.5)
Duration of HT use
(years) 6
Never 114,271 / 149 1.0 (ref) 114,420 / 94 1.0 (ref) 170 / 83 1.0 (ref) 107 / 67 1.0 (ref)
1 22,819 / 43 1.3 (0.9–1.9) 22,862 / 12 0.7 (0.4–1.2) 42 / 28 1.2 (0.6–2.5) 39 / 11 0.4 (0.1–1.0)
2–4 19,032 / 32 1.0 (0.7–1.5) 19,064 / 9 0.6 (0.3–1.1) 44 / 15 0.5 (0.2–1.1)
5 15,834 / 27 1.0 (0.7–1.6) 15,861 / 7 0.4 (0.2–0.9) 49 / 19 0.6 (0.3–1.4) 26 / 5 0.1 (0.03–0.6)
p for trend among
menopausal hormones
users
0.2 0.4 - -
CIN 3: cervical intraepithelial neoplasia grade 3; CIS: carcinoma in situ; ICC: invasive cervical cancer; HR: hazard ratio; OR: odds ratio; CI: conﬁdence
interval; IUD: intrauterine device; OC: oral contraceptives; HT: hormone therapy. The number of cases does not add up the total number of cases because
of missing values. Bold font indicates a statistically signiﬁcant effect (p<0.05).
1 Models were adjusted by body mass index, marital status, level education, physical activity, smoking habits, number of full-term pregnancies and
menopausal status with HT use.
2 Conditional regression models were adjusted by HPV L1 serology, Chlamydia trachomatis serology, Human herpesvirus 2 serology, body mass index,
marital status, level education, physical activity, smoking habits, number of full-term pregnancies and menopausal status with HT use. See methods for list
matching variables.
3 Excludes Bilthoven, Sweden and Norway because information was not collected for this variable.
4 Among OC users (excluding non OC users).
5 Excludes Bilthoven, France, Germany, Sweden, Denmark and Norway because information was not collected for this variable.
6 Among peri and postmenopausal women (excluding premenopausal women) and models also adjusted by OC use and duration but not adjusted by
menopausal status with HT use. 7 Risk estimates were not estimated due to lack of power in the model.
doi:10.1371/journal.pone.0147029.t002
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Analyses restricted to countries with screening programs (United Kingdom, Sweden, Den-
mark, Norway) did not substantially change the magnitude of the associations for the several
risk factors (data not shown).
Table 3 shows associations restricted to all cases and HPV L1 seropositive controls in the
nested case-control study. In this analysis number of FTP was strongly associated with an
increased risk of CIN3/CIS. For induced abortions we found opposite effects for CIN3/CIS ver-
sus ICC (OR = 0.5 and OR = 1.7 respectively, for ever versus never). Current use and duration
of OCs increased the risk of both CIN3/CIS and ICC although the associations were not statis-
tically significant. HT use and duration was inversely and significantly associated with ICC.
Finally, IUD use was inversely associated with both CIN3/CIS and ICC risk without statistical
significance, although when we combined CIN3/CIS and ICC the significance emerged
(OR = 0.7, 95% CI: 0.5–0.96; data not shown). Associations were broadly similar in analyses
restricted to all cases and high-risk HPV seropositive controls and in analyses including only
HPV seropositive cases and controls (data not shown), revealing a significant inverse associa-
tion between IUD use and ICC among HPV seropositive women (OR = 0.3, 95% CI: 0.1–0.9;
data not shown).
Discussion
The results of this large prospective cohort study show that certain endogenous and exogenous
hormonal factors appear to be related to cervical carcinogenesis. Thus the risk of cervical pre-
cancer increased with increasing number of FTP and duration of OC use, and decreased with
increasing years since last OC use among past users. For ICC, the risk increased with number
of abortions and duration of OC use, and decreased with increasing duration of HT. A reduced
risk of ICC was also observed among IUD users in the nested case-control study. Globally the
associations were somewhat stronger in the cohort study than in the nested case-control study.
The case-control study is useful to support the results obtained in the cohort study since it
allowed for the additional adjustment of serological markers of HPV exposure and other STIs.
OC use
Consistent with results from previously published pooled analyses [7,17], our study highlighted
strong and positive associations between OC use and risk of cervical cancer and pre-cancer;
specifically, the risk increased with duration of use and decreased with cessation of use. While
the IARC collaborative study found a relative risk of 1.6 for long-term OC users with a signifi-
cant trend, Moreno et al. observed a stronger association (OR = 4.0). In line with our findings,
these two studies also found a reduced risk of cervical cancer for users who ceased OCs
(RR = 0.8 and OR = 0.5, respectively). Other prospective studies did not find associations
between OCs and CIN3/CC risk [18–20]. Analyses combining duration and recency of use
evaluated in our study found a trend of lower CIN3/CIS risk with cessation of use for both
short and long-term OC users, reinforcing the null association among past users and the higher
risk among current users. The IARC collaborative study has also analyzed these factors in com-
bination, obtaining similar patterns of trend, but unlike our study, for both CIN3/CIS and ICC
risk.
Since HPV is the necessary cause of CC, analyses including some measure of HPV infection
are needed to assess potential residual confounding. In our nested case-control study we
included the adjustment by HPV serology, and we evaluated OC use and CC risk among all
cases and HPV seropositive controls. As already discussed, these results were broadly similar to
those obtained in the cohort study, suggesting that we can reasonably rule out a large con-
founding effect due to HPV infection in our associations. In the last 10 years, most of the
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Table 3. Multivariate odds ratios for the association between factors related to endogenous and exogenous hormones and CIN3/CIS and ICC
cases among all cases and HPV L1 seropositive control women in the nested case-control study.
Risk factor Among all cases and HPV L1 seropositive control women
CIN3/CIS ICC
Controls / Cases OR (95% CI) Controls / Cases OR (95% CI)
Number of FTP 1
Never 64 / 51 1.0 (ref) 16 / 30 1.0 (ref)
Ever 250 / 288 2.0 (1.2–3.2) 122 / 131 0.6 (0.3–1.4)
1 71 / 71 1.4 (0.8–2.6) 21 / 26 0.9 (0.3–2.6)
2 99 / 132 2.3 (1.3–4.0) 69 / 53 0.4 (0.2–1.0)
3 47 / 46 2.0 (1.0–4.0) 24 / 28 0.7 (0.3–2.0)
4 24 / 28 2.6 (1.2–5.9) 7 / 16 1.2 (0.3–4.6)
p for trend among ever ftp 0.2 0.3
Number of induced abortions 1,3
Never 127 / 166 1.0 (ref) 77 / 70 1.0 (ref)
Ever 58 / 45 0.5 (0.3–0.8) 29 / 41 1.7 (0.8–3.9)
1 42 / 36 0.5 (0.3–0.9) 18 / 26 2.0 (0.8–5.0)
2 16 / 9 0.4 (0.1–0.9) 11 / 15 1.4 (0.5–4.3)
IUD use 2,3
Never 143 / 160 1.0 (ref) 78 / 106 1.0 (ref)
Ever 86 / 82 0.7 (0.4–1.1) 37 / 28 0.6 (0.3–1.2)
OC use 2
Never 103 / 99 1.0 (ref) 59 / 56 1.0 (ref)
Ever 214 / 244 1.1 (0.7–1.6) 80 / 109 1.7 (0.9–3.3)
Past 182 / 197 1.1 (0.7–1.6) 70 / 86 1.6 (0.8–3.1)
Current 26 / 41 1.6 (0.8–3.2) 10 / 17 2.7 (0.8–9.1)
Duration of OC use (years) 2
Never 103 / 99 1.0 (ref) 59 / 56 1.0 (ref)
4 82 / 82 1.0 (0.7–1.7) 32 / 36 1.4 (0.6–3.0)
5–9 53 / 54 0.9 (0.5–1.6) 15 / 22 2.1 (0.8–5.5)
10 60 / 94 1.6 (0.9–2.6) 31 / 42 1.8 (0.8–4.2)
p for trend among OC users 0.1 0.3
HT use 4,5
Never 84 / 83 1.0 (ref) 54 / 67 1.0 (ref)
Ever 77 / 84 1.0 (0.6–1.7) 39 / 18 0.3 (0.1–0.6)
Past 23 / 17 0.6 (0.3–1.4) 10 / 8 0.5 (0.1–1.7)
Current 51 / 61 1.2 (0.7–2.2) 29 / 10 0.2 (0.1–0.5)
Duration of HT use (years) 4,5
Never 84 / 83 1.0 (ref) 54 / 67 1.0 (ref)
1 18 / 28 1.4 (0.6–3.0) 21 / 11 0.3 (0.1–0.8)
2–4 24 / 15 0.5 (0.2–1.2)
5 28 / 19 0.7 (0.3–1.6) 14 / 5 0.2 (0.05–0.8)
p for trend among menopausal hormones users 0.3 -
CIN3: cervical intraepithelial neoplasia grade 3; CIS: carcinoma in situ; ICC: invasive cervical cancer; OR: odds ratio; CI: conﬁdence interval; FTP: full-
term pregnancy; IUD: intrauterine device; OC: oral contraceptive; HT: hormone therapy. The number of cases and controls does not add up the total
number because of missing values. Bold font indicates a statistically signiﬁcant effect (p<0.05).
1 Unconditional regression models were adjusted by age, country, Chlamydia Trachomatis serology, Human herpesvirus 2 serology, body mass index,
marital status, level education, physical activity, smoking habits, OC use and duration and menopausal status with HT use.
2 Unconditional regression models were adjusted by age, country, Chlamydia Trachomatis serology, Human herpesvirus 2 serology, body mass index,
marital status, level education, physical activity, smoking habits, number of full-term pregnancies and menopausal status with HT use.
3 Excludes Bilthoven, Sweden and Norway because information was not collected for this variable.
4 Unconditional regression models were adjusted by age, country, Chlamydia Trachomatis serology, Human herpesvirus 2 serology, body mass index,
marital status, level education, physical activity, smoking habits, OC use and duration and number of full-term pregnancies.
5 Among post and perimenopausal women (excluding premenopausal women).
doi:10.1371/journal.pone.0147029.t003
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published studies have also considered HPV infection in their analyses, and the results were
globally comparable to those for all women. On the other hand, the very few studies that have
used serology as HPV measurement found contradictory results [21–23]. Even though our
study did not explicitly collect data related to sexual behavior we were able to adjust for sero-
logical markers of HPV, CT and HHV-2, as well as for marital status, which can all be consid-
ered good surrogate indicators of sexual behavior and risk of HPV exposure [24]. Since the
results were very consistent with these adjustments, we were reassured that the potential effects
of confounding by sexual behavior on our reported associations were minimal. Behavioral fac-
tors related to cervical cancer screening may also confound these associations. Again, even
though the study did not collect individual data on screening practices, we systematically
adjusted for surrogate markers of screening-related behavior such as number of pregnancies
and variables related to contraceptive methods used in the past that may somewhat reduce the
potential confounding effects due to screening practices. Also it is important to note that other
studies that have adjusted for cervical screening did find positive associations with CC risk
[7,17].
A possible mechanism to explain the associations between OC use and CC risk is that estro-
gens and progestogens may interact with hormone receptors, mainly progesterone, present in
cervical tissue and influence the natural history of HPV infection. Specifically, sex steroid hor-
mones are thought to enhance the expression of HPV 16 E6 and E7 oncogenes stimulating the
degradation of p53 tumor suppressor genes and enhancing the ability of the viral DNA to
transform cells and induce carcinogenesis [7,9,25,26]. These potential mechanisms are some-
what consistent with data from transgenic mouse models showing that estrogen and its nuclear
receptor promote CC in combination with HPV oncogenes, but there are not in line with the
observation that progesterone inhibits cervical carcinogenesis in mice [27,28].
Parity
We found contrasting results between parity and risk of CIN3/CIS and ICC. Thus, while
women with high parity had a higher risk of CIN3/CIS than nulliparous women, no associa-
tions were found with ICC. We also found that this association with high parity was present in
each level of OC duration with a synergistic effect between the two variables. These results are
in concordance with results from some [20,23] but not all [8,18,19,29] studies. The IARC col-
laborative study [8] and the IARC multicenter study [29] consistently found a significantly
higher risk of CIN3/CIS and ICC among women with high parity. In contrast, two prospective
studies conducted by Castle et al. [18,19] and a case-control study done in the US [23] did not
find a significant association between parity and risk of CIN3/ICC. The lack of association
between high parity and ICC risk found in our study could be explained by screening practices
related to parity since it is likely that nulliparous women tend to be less screened than parous
women. Hence, screening may act as a negative confounder, reducing the association between
FTP and ICC risk. Globally the literature supports for an association between high parity and
cervical cancer and pre-cancer risk.
As discussed in relation to OC use, these associations may be confounded by a number of
other factors. However, adjustment by proxy measures of HPV exposure and sexual behavior
did not change our risk estimates. In addition, two pooled analyses that adjusted their models
by cervical screening practices obtained also similar results [8,29].
A possible biological mechanism for these associations could be that the elevated levels of
estrogen and especially progesterone during pregnancy are responsible for the alterations in
the squamo-columnal junction occurring during pregnancy, maintaining the transformation
zone on the exocervix for many years. This would facilitate the direct exposure to HPV
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contributing to HPV persistence and progression to cervical neoplasia and cancer [8,20,29].
Another possible mechanism is immunosuppression linked to pregnancy which might enhance
the role of HPV in cervical carcinogenesis [8].
HT use
Our findings provide evidence for a reduction in ICC risk among peri- and postmenopausal
women using HT, an effect that was stronger with longer duration of use. We found very few
studies evaluating HT and CC [26,30]. Overall, the literature rules out positive associations. If
anything, most studies found weak inverse associations that rarely reached statistical signifi-
cance. In assessing HT, however, it is important to consider the hormonal composition of these
treatments. The IARC review reported an increased risk for breast and endometrial cancer in
the 1970s among postmenopausal women using estrogen only therapy, and this triggered
health authorities to modify the hormonal composition of HT [6]. Even though our data on
HT formulation were very limited, menopausal estrogens alone were associated with an
increased risk of CIN3/CIS and combined HT were inversely associated with ICC. Other stud-
ies found some evidence for a reduced risk of ICC with ever use of estrogen therapy as well as
duration as compared with never use [30–32]. When HT also included progesterone, the
inverse association with ICC risk still remained both in our study as well as in other studies
[30,33].
As noted previously, one of the limitations of this study is the lack of accurate individual
screening history that may indeed influence the effects of HT use on CC risk. Thus, the inverse
associations found with ICC, an outcome more susceptible to screening bias, could be some-
what overestimated. One possible explanation of this effect is that women who take HT are
more frequently screened than non users, being consequently diagnosed and treated earlier of
pre-cancerous lesions. Nevertheless, when we stratified analyses by proxy measures of screen-
ing such as parity and OC use, the inverse association remained (data not shown). The intrinsic
mechanisms that might explain the biology of these potential associations are currently
unknown. Data from HPV transgenic mouse models suggest that estrogens promote cervical
carcinogenesis and progesterone inhibits CC [27,28]. However, our results, limited by the low
number of subjects, are only partially consistent with these findings.
Induced abortions
An increased risk of ICC and a reduced risk of CIN3/CIS were found among women reporting
an induced abortion. Globally, the literature with regard to cervical cancer and pre-cancer risk
and induced abortions is inconclusive and our results were in line with some [24,34–36] but
not all [29,37,38] studies. More data are needed to better explore these potential associations.
Menstrual lifespan
We observed a decreased risk of both CIN3/CIS and ICC risk with increasing cumulative years
of menstrual cycles. Longer menstrual lifespan is implicitly associated with shorter OC use
duration and lower parity. However, the advantage of using menstrual lifespan is that includes
in a single indicator combined information on the cumulative exposure to some endogenous
and exogenous hormones taking into account the actual hormonal lifespan of the woman, pro-
viding thus more robustness in the risk estimates. It is interesting to note that even though this
variable has been used in studies of other hormone-related cancers such as breast, ovarian and
endometrial, no previous studies of CC have been identified in the literature.
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IUD use
We found a non significant decreased risk of both CIN3/CIS and ICC among IUD users in the
nested case-control study that reached statistical significance in the analyses restricted to all cases
and HPV seropositive controls when combining CIN3/CIS and ICC cases (OR = 0.7, 95% CI:
0.5–0.96; data not shown) and in the analyses restricted to HPV seropositive women for ICC risk
(OR = 0.3, 95% CI: 0.1–0.9; data not shown). The full case-control study and the different strati-
fied analyses consistently found that IUD use was inversely associated with both CIN3/CIS and
ICC risk. Few studies have evaluated associations between IUD use and CC risk with inconsistent
results [20,23,37,39]. In a population-based study conducted in the US, Shields and colleagues
found a protective effect between duration of IUD and ICC (OR = 0.3, 95% CI: 0.2–0.8, for
5 years of IUD use) [23]. In a large pooled analysis, Castellsagué and colleagues reported a
strong inverse association between IUD use and ICC (OR = 0.5, 95% CI: 0.4–0.7) [39]. Other
studies, however, have not confirmed these findings, although the use of a combined outcome
(CIN3/CIS and ICC) or a low number of cases could explain these discrepancies [20,37]. Even
though we adjusted for major risk factors such as past exposure to HPV, STIs and sexual behav-
ior, it is true that we cannot completely rule out a residual confounding effect exerted by CC
screening. It is important to note that the study by Castellsagué did adjust the analyses for cervi-
cal HPV DNA, age at first sex, and number of PAP smears, and still found a statistically signifi-
cant inverse association. One possible mechanism that could explain this potential protective
effect is through a device-related inflammatory reaction in the cervix and endocervix that could
influence the subsequent likelihood of HPV persistence and/or progression to CC [39].
SCC versus adenocarcinoma
Globally, the associations found between both exogenous and endogenous hormones and SCC
risk were comparable to those obtained in models evaluating CIN3/CIS and ICC risk (data not
shown). Concerning the risk of invasive adenocarcinoma, even though there were very few
cases, an association was found with increasing number of FTP, in addition to OC use and HT,
in the cohort study (data not shown). In concordance with our study, the IARC collaborative
reanalysis evaluating risk factors for SCC and adenocarcinoma obtained an increased risk for
each histological type with increasing duration of OC use [40]. Contrary to this and to another
study [41], our results did not indicate that high parity is a risk cofactor for developing SCC,
probably due to screening bias. Concerning HT use and contrary to our findings, Lacey and
colleagues found that exogenous estrogens, especially unopposed estrogens, were positively
associated with adenocarcinomas [30]. However, since both studies accounted for small num-
ber of cases, these findings should be cautiously interpreted.
Strengths and limitations
Our study has several strengths including its prospective, population-based design in most of
the countries, a large sample size that embraces various regions in Europe, and the inclusion of
two disease outcomes: CIN3/CIS and ICC. In addition, our inclusion of a nested case-control
study within the cohort allowed us to determine and take into account biomarkers of past
exposure to STIs such as HPV, CT and HHV-2.
Nevertheless, our study design failed to consider direct markers of HPV infection, cervical
cancer screening practices or sexual behavior, not only at recruitment but also during follow-
up, as none of the assessed risk factors or potential confounding variables was reassessed after
recruitment. Since these risk factors could and most likely did change in an unknown direction
during follow-up, our associations may have led to under- or overestimation of the real effects
on CC risk. Another limitation was the low sensitivity of the HPV serology technique, as only
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half of infected women seroconvert, and a potential misclassification cannot be totally ruled
out [12].
Conclusions
This study contributes strong evidence to consider high parity and long-term OC use impor-
tant risk factors for cervical cancer and pre-cancer. These risk factors would act not indepen-
dently but rather as cofactors that interact with HPV to induce cervical carcinogenesis. Our
study also provides some evidence that IUD use and HT confer a reduced risk of cervical can-
cer, but these findings need further confirmation. Despite the clear involvement of hormones
in cervical carcinogenesis, and from a public health point of view, adherence to current screen-
ing recommendations will certainly minimize the potential increased risk of CC associated
with some of these hormonal risk factors.
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